Clay B Siegall
CEO, President at Immunome Inc. (IMNM); Director at Shattuck Labs, Inc. (STTK)
Purchase track record
Above average. Based on 5 purchases with a full 90 days of price history.
66
Avg. 90-day return+7.3%
vs. S&P 500+6.4%
Beat the market40%
Paper profit on buys+$15K
Total bought / sold$2.0M / $0
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jun 11SEC | STTKShattuck Labs, Inc. | Buy | 62,500318,608 held (+24%) | $4.00 | $250K | +49.2% |
| Mar 31SEC | IMNMImmunome Inc. | Buy | 25,450690,704 held (+4%) | $19.67 | $501K | -0.6% |
| Dec 30SEC | IMNMImmunome Inc. | Buy | 4,729665,254 held (+1%) | $21.15 | $100K | -7.6% |
| Dec 22SEC | IMNMImmunome Inc. | Buy | 7,278860,525 held (+1%) | $20.48 | $149K | -4.5% |
| Dec 18SEC | IMNMImmunome Inc. | Buy | 46,511853,247 held (+6%) | $21.50 | $1000K | -9.1% |
- Buy
Director Clay B Siegall bought $250K of STTK at $4.00 — first open-market purchase in our records; raises the stake by 24%.
- Buy
CEO, President Clay B Siegall bought $1000K of IMNM at $21.50 — first open-market purchase in our records.